Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 24.8% in March

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 2,850,000 shares, a decrease of 24.8% from the February 28th total of 3,790,000 shares. Currently, 11.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,830,000 shares, the days-to-cover ratio is currently 1.6 days.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 17.9% in the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after buying an additional 42,376 shares in the last quarter. EMC Capital Management grew its stake in Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after acquiring an additional 26,134 shares during the last quarter. Drive Wealth Management LLC purchased a new position in Reviva Pharmaceuticals during the 4th quarter valued at about $36,000. Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals during the fourth quarter worth about $84,000. Finally, Tang Capital Management LLC purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at about $308,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RVPH has been the topic of several analyst reports. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 target price on the stock. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Friday, January 10th. HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Finally, Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Reviva Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $11.40.

Reviva Pharmaceuticals Trading Down 7.3 %

Shares of Reviva Pharmaceuticals stock opened at $1.01 on Friday. The company has a 50-day moving average of $1.53 and a two-hundred day moving average of $1.47. The stock has a market cap of $33.78 million, a PE ratio of -0.91 and a beta of -0.09. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.28.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.